Two Sigma Investments, LP Acelrx Pharmaceuticals Inc Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.35 $13,066 - $22,866	65,333 New	65,333 $14,000
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $47,565 - $78,506	-46,180 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $57,725 - $127,918	46,180 New	46,180 $79,000
Q3 2020 Nov 16, 2020	SELL	$1.01 - $1.81 $107,645 - $192,909	-106,580 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.03 - $1.69 $109,777 - $180,120	106,580 New	106,580 $129,000
Q1 2020 May 15, 2020	SELL	$0.76 - $2.07 $19,212 - $52,329	-25,280 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.66 - $2.4 $41,964 - $60,672	25,280 New	25,280 $53,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $149,402 - $279,595	-71,144 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$2.35 - $3.83 $1.15 Million - $1.87 Million	-488,264 Reduced 87.28%	71,144 $248,000
Q4 2018 Feb 14, 2019	BUY	$2.13 - $4.8 $1.06 Million - $2.39 Million	498,664 Added 820.93%	559,408 $1.29 Million
Q3 2018 Nov 14, 2018	BUY	$2.6 - $4.6 $157,934 - $279,422	60,744 New	60,744 $234,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.